bimatoprost ocular insert

Bimatoprost insert offers noninvasive platform for early glaucoma patients A 19-month, open-label study of a novel bimatoprost, sustained-release ocular insert shows good safety and efficacy. The insert is polymer ring that sits atop the eye in the conjunctival fornix. Phase III trials are expected to begin in 2017.
Drug therapies, delivery systems advance for glaucoma carePharmacologic products and devices in development continue to gain momentum in the glaucoma treatment armamentarium.